190 related articles for article (PubMed ID: 28944729)
1. Using Performance-Based Risk-Sharing Arrangements to Address Uncertainty in Indication-Based Pricing.
Yeung K; Li M; Carlson JJ
J Manag Care Spec Pharm; 2017 Oct; 23(10):1010-1015. PubMed ID: 28944729
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
3. The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+ metastatic breast cancer.
Jiao B; Garrison LP
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):497-504. PubMed ID: 33645393
[TBL] [Abstract][Full Text] [Related]
4. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
Buyukkaramikli NC; Wigfield P; Hoang MT
Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
[TBL] [Abstract][Full Text] [Related]
5. Value-Based Pricing and Budget Impact Analysis for Multi-Indication Drugs: A Case Study of Immunotherapies.
Ha SY; Kang DW; Jung HI; Lee EK; Park MH
Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409788
[TBL] [Abstract][Full Text] [Related]
6. Paying for Cures: How Can We Afford It? Managed Care Pharmacy Stakeholder Perceptions of Policy Options to Address Affordability of Prescription Drugs.
Yeung K; Suh K; Basu A; Garrison LP; Bansal A; Carlson JJ
J Manag Care Spec Pharm; 2017 Oct; 23(10):1084-1090. PubMed ID: 28944726
[TBL] [Abstract][Full Text] [Related]
7. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines.
Genuino AJ; Chaikledkaew U; Guerrero AM; Reungwetwattana T; Thakkinstian A
BMC Health Serv Res; 2019 Nov; 19(1):874. PubMed ID: 31752849
[TBL] [Abstract][Full Text] [Related]
8. Increasing Divergence in Drug Prices Between the United States and Germany After Implementation of Comparative Effectiveness Analysis and Collective Price Negotiations.
Berkemeier F; Whaley C; Robinson JC
J Manag Care Spec Pharm; 2019 Dec; 25(12):1310-1317. PubMed ID: 31778624
[TBL] [Abstract][Full Text] [Related]
9. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer.
Garrison LP; Veenstra DL
Value Health; 2009; 12(8):1118-23. PubMed ID: 19624617
[TBL] [Abstract][Full Text] [Related]
10. The Role of Indication-Based Pricing in Future Pricing and Reimbursement Policies: A Systematic Review.
Preckler V; Espín J
Value Health; 2022 Apr; 25(4):666-675. PubMed ID: 35227598
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.
Le QA; Bae YH; Kang JH
Breast Cancer Res Treat; 2016 Oct; 159(3):565-73. PubMed ID: 27572338
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.
Neyt M; Huybrechts M; Hulstaert F; Vrijens F; Ramaekers D
Health Policy; 2008 Aug; 87(2):146-59. PubMed ID: 18164510
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.
Leung W; Kvizhinadze G; Nair N; Blakely T
PLoS Med; 2016 Aug; 13(8):e1002067. PubMed ID: 27504960
[TBL] [Abstract][Full Text] [Related]
14. IMPLICATIONS OF GLOBAL PRICING POLICIES ON ACCESS TO INNOVATIVE DRUGS: THE CASE OF TRASTUZUMAB IN SEVEN LATIN AMERICAN COUNTRIES.
Pichon-Riviere A; Garay OU; Augustovski F; Vallejos C; Huayanay L; Bueno Mdel P; Rodriguez A; de Andrade CJ; Buendía JA; Drummond M
Int J Technol Assess Health Care; 2015 Jan; 31(1-2):2-11. PubMed ID: 25989703
[TBL] [Abstract][Full Text] [Related]
15. Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective.
Clarke CS; Hunter RM; Shemilt I; Serra-Sastre V
PLoS One; 2017; 12(3):e0172731. PubMed ID: 28248984
[TBL] [Abstract][Full Text] [Related]
16. Real-World Setting Cost-Effectiveness Analysis Comparing Three Therapeutic Schemes of One-Year Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer from the Cyprus NHS Payer Perspective.
Ioannou SS; Marcou Y; Kakouri E; Talias MA
Int J Environ Res Public Health; 2020 Jun; 17(12):. PubMed ID: 32560485
[TBL] [Abstract][Full Text] [Related]
17. Price Models for Multi-indication Drugs: A Systematic Review.
Campillo-Artero C; Puig-Junoy J; Segú-Tolsa JL; Trapero-Bertran M
Appl Health Econ Health Policy; 2020 Feb; 18(1):47-56. PubMed ID: 31523756
[TBL] [Abstract][Full Text] [Related]
18. Pricing Treatments Cost-Effectively when They Have Multiple Indications: Not Just a Simple Threshold Analysis.
Goldhaber-Fiebert JD; Cipriano LE
Med Decis Making; 2023; 43(7-8):914-929. PubMed ID: 37698120
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis.
Dashputre AA; Kamal KM; Pawar G
J Manag Care Spec Pharm; 2017 Jun; 23(6):666-676. PubMed ID: 28530523
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
